Platinum Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Platinum Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-62,200	Closed	-$2M	–	78
2017 Q1	$2M	Hold	62,200	–	–	0.06%	49
2016 Q4	$2.25M	Hold	62,200	–	–	0.07%	43
2016 Q3	$2.86M	Hold	62,200	–	–	0.07%	48
2016 Q2	$3.12M	Hold	62,200	–	–	0.08%	45
2016 Q1	$3.33M	Hold	62,200	–	–	0.07%	49
2015 Q4	$4.08M	Hold	62,200	–	–	0.09%	44
2015 Q3	$3.51M	Hold	62,200	–	–	0.1%	41
2015 Q2	$3.68M	Hold	62,200	–	–	0.07%	47
2015 Q1	$3.88M	Hold	62,200	–	–	0.08%	54
2014 Q4	$3.58M	Hold	62,200	–	–	0.07%	59
2014 Q3	$3.34M	Buy	62,200 +4,000	+7%	+$212K	0.07%	58
2014 Q2	$3.05M	Buy	58,200 +5,000	+9%	+$256K	0.05%	62
2014 Q1	$2.81M	Hold	53,200	–	–	0.05%	61
2013 Q4	$2.13M	Hold	53,200	–	–	0.04%	55
2013 Q3	$2.01M	Buy	53,200 +6,000	+13%	+$234K	0.04%	56
2013 Q2	$1.85M	Buy	+47,200	New	+$1.84M	0.04%	49

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Platinum Investment Management's TEVA Position: Q2 2017 in Review

Platinum Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 62,200 shares — an estimated $2M sold.

Platinum Investment Management first reported a position in TEVA in Q2 2013 and held it in 16 quarters. The position peaked at $4.08M in Q4 2015. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Platinum Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Platinum Investment Management sold 62,200 Teva Pharmaceuticals shares in Q2 2017, an estimated $2M.
Platinum Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Platinum Investment Management's Teva Pharmaceuticals position peaked at $4.08M in Q4 2015.
648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Platinum Investment Management's 13F filing for Q2 2017, filed 15 Aug 2017.